Brain diseases are often chronic, incurable and represent an enormous burden to patients, families, and society. At Biohaven, we are committed to improving the lives of patients suffering from central nervous system disorders by advancing first-in-class and best-in-class therapies. Biohaven Spotlights Nurtec ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive.
Services
Biohaven is a clinical-stage biopharmaceutical company with proven leadership in industry and academic settings. Our portfolio is comprised of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders.
Our progress is fueled by an entrepreneurial organizational structure and an impressive range of experience in drug development along with the confident support of top-tier biopharma investors.
Our progress is fueled by an entrepreneurial organizational structure and an impressive range of experience in drug development along with the confident support of top-tier biopharma investors.
The Biohaven culture emphasizes passion, teamwork and high-performance to create value for patients, investors, and employees. We employ a decentralized leadership approach, with small teams working closely together, to foster effective and efficient drug development. Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb.
The Biohaven culture emphasizes passion, teamwork and high-performance to create value for patients, investors, and employees. We employ a decentralized leadership approach to empower local teams, those closest to our customers, to effectively engage, educate and deliver differentiated commercial solutions to clinicians, patients and their family members.
Biohaven's first clinical candidate targets CD38, a validated approach in multiple myeloma (MM). Biohaven is initiating a clinical trial in newly diagnosed, minimum residual disease positive (MRD+), post-autologous stem cell transplant patients with a CD38-targeting ARM (KP1237) as a combination product with autologous NK cells and low-dose IL-2.
Natural Killer (NK) Cells are a type of immune effector cell that can recognize and destroy non-self targets and certain diseased cell. NK cells do not target specific protein epitopes like T cells of the adaptive immune system. Biohaven ARMs are being used to redirect engineered NK cells localize at sites of specific disease cell targets for enhanced efficacy.
Reviews
Be the first to review Biohaven Pharmaceutical Holding.
Write a Review
